Edwards Lifesciences’ EW fourth-quarter performance was backed by its most comprehensive structural heart disease portfolio. The Surgical Structural Heart business is benefiting from the strong ...

A federal court granted summary judgment to Edwards Lifesciences LLC on a Title VII failure to accommodate religious observance claim of a senior cardiovascular specialist who alleged that Edwards ...

This was the stock's second consecutive day of losses.

Shares of Edwards Lifesciences Corp. rallied 6.92% to $75.82 Wednesday, on what proved to be an all-around grim trading ...

Edwards Lifesciences Corp. engages in the patient-focused medical innovations for heart disease and critical care monitoring. Its products are categorized into three areas: Transcatheter Heart ...

Edwards Lifesciences reports strong contributions from all product groups ??? TAVR, TTMT and surgical structural heart ??? in ...

Edwards Lifesciences stock popped Wednesday on strong sales of its TAVR procedures, leading to a top- and bottom-line beat. On Tuesday, Edwards Lifesciences (NYSE:EW) reported fourth-quarter sales ...

Barclays analyst Matt Miksic raised the firm’s price target on Edwards Lifesciences (EW) to $90 from $88 and keeps an Overweight rating on the ...

Canaccord raised the firm’s price target on Edwards Lifesciences (EW) to $71 from $66 and keeps a Hold rating on the shares. The firm said they ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

A novel transcatheter-implanted system that shunts blood flow from the left to right atrium through the coronary sinus has ...